Trichotillomania Comorbid with Schizophrenia by Othman, Zahiruddin & Fadzil, Nor Asyikin
INTRODUCTION
Trichotillomania (TTM) has been mostly a comorbid with other 
obsessive-compulsive related disorders (OCRD), notably skin-picking 
disorder. Until recently there have been only few reports of TTM in 
schizophrenia1). Here, we present a case of TTM in a young man with 
schizophrenia to add to the scarce literature available on this comorbidi-
ty and discuss the possible etiology.
CASE
A 25-year-old single Malay man with 2 years history of schizophre-
nia presented to our clinic with a new complaint. Shyly, he took off his 
Figure 1. Initial presentation of trichotillomania. The patient was 
on quetiapine 500 mg ON.
Figure 2. One year after escitalopram 10 mg ON was added to 
quetiapine 500 mg ON.
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cap which that he wore to avoid embarrassment showing bald patches 
on his scalp. For the past 1 year, he developed hair pulling which was 
preceded by mounting anxiety and was relieved afterward. He mini-
mized the hair loss by claiming that most of the time he just twirled and 
pulled it lightly until it gave out popping sounds. There was no history 
of eating the hair. 
Past psychiatric history revealed that his initial presentation was 4 
years prior when he presented with severe unremitting panic attacks for 
which he was treated with escitalopram 15 mg nocte and alprazolam 0.5 
mg tds. He also had mild and transient doubts over the cleanliness of his 
undergarment whether it was acceptable during prayers. One and a half 
year later, he developed auditory hallucinations for the first time. Soon 
he became depressed with suicidal thoughts as the voices became more 
prominent commanding him to kill himself. He was discharged well 
after 2 weeks of admission with quetiapine 500 mg nocte. During the 
follow-ups, he had tactile hallucinations described as being touched and 
sexually aroused by invisible Jin. His father and brother were diagnosed 
with schizophrenia obsessive-compulsive disorder, respectively. 
Escitalopram 10 mg nocte was added to existing queatiapine 500mg 
nocte. Having seen the long-term effect of schizophrenia on his father 
and being unemployed caused him to constantly worry about his future. 
He was referred for psychosocial rehabilitation. He sought solace in 
religion through activities such as prayer and dhikr. About a year after 
later, the bald patches on his scalp had become smaller in size but not 
completely disappear. As he was busy working in a nearby hypermarket, 
he was able to distract his mind from the worrying thoughts and thus 
had greater control over his hair pulling behavior.
DISCUSSION
DSM-5 brings TTM more in line with repetitive and ritualized 
behavior and impulses in obsessive-compulsive and related disorders 
(OCRD) and distinguishes it from its previous roots with impulse con-
trol disorders2). Both TTM and OCD have underlying problems with 
inhibitory control but perhaps stemming from different motivating fac-
tors driving the behaviors3).
This case illustrates a number of complex and interrelated psycho-
pathology such as anxiety, depression, psychosis, obsession and com-
pulsion. The initial presentation of this patient was panic attacks and 
obsessive-compulsive symptoms. Later on, he developed a psychotic 
episode accompanied by severe depression with suicidal ideations even 
though he was already on adequate dose of antidepressant and benzodi-
azepine. As all these symptoms stabilized during the follow-up, he pre-
sented with yet another symptom which was TTM.
In this case, the TTM is most likely a comorbid with schizophrenia 
due to the fact that the hair pulling behavior remains when all the other 
symptoms including panic attacks, depression and psychosis were mini-
mal or absent. In contrast, if TTM was in response to commanding hal-
lucinations or delusions, we would expect improvement in tandem with 
psychotic symptoms resolution with antipsychotics treatment4). 
In second generation antipsychotics (SGA)-induced obsessive-com-
pulsive symptoms (OCS), a patient without a previous history of OCS 
develops these phenomena during antipsychotic treatment5). A clear 
association and possible causal interaction between SGA, in particular 
clozapine, and the de novo occurrence of OCS has been reported6,7) In 
this patient, the onset of OCS preceded the psychotic symptoms and ini-
tiation of SGA. The onset of TTM however, was during the antipsychot-
ic treatment. Therefore, the role of SGA in this case is to aggravate 
existing OCS rather than inducing de novo OCS. 
Selective serotonin reuptake inhibitors (SSRI) and antipsychotics 
are the most commonly use pharmacological treatments for TTM8). 
Olanzapine9) and quetiapine10) for instance, have been reported as a use-
ful treatment for TTM. As this patient was already on quetiapine, an 
SSRI was added which can also treat the concomitant anxiety symp-
toms.
CONCLUSION
Schizophrenia patient with prodromal OCS is probably at increased 
risk of developing TTM while on atypical antipsychotics treatment. 
Atypical antipsychotics and SSRI combination therapy is a useful strate-
gy in such patient. In addition, psychosocial intervention will be helpful 
to alleviate the ongoing stressor and reduce the hair pulling behavior.
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